35Pharma Overview

  • Year Founded
  • 2021

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 45

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $1.01B

35Pharma General Information

Description

Operator of a biopharmaceutical company intended for pulmonary hypertension and musculoskeletal disorders. The company combines protein engineering expertise with a deep understanding of transforming growth factor-beta structure-function relationships to design potent ligand traps for cardiovascular and metabolic diseases, enabling scientists to develop biologics for treating patients.

Contact Information

Website
www.35pharma.com
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 750 Saint Laurent Boulevard
  • Suite 101
  • Montreal, Quebec H2Y 2Z4
  • Canada
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Acquirer
GSK
Vertical(s)
Life Sciences
Corporate Office
  • 750 Saint Laurent Boulevard
  • Suite 101
  • Montreal, Quebec H2Y 2Z4
  • Canada

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

35Pharma Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Merger/Acquisition 14-Apr-2026 $1.01B Completed Generating Revenue
3. Later Stage VC 15-Sep-2025 Completed Generating Revenue
2. Later Stage VC (Series C) 22-Nov-2024 $53M $70M Completed Generating Revenue
1. Early Stage VC 19-Dec-2022 $17M $17M Completed Generating Revenue
To view 35Pharma’s complete valuation and funding history, request access »

35Pharma Patents

  • 21

    Total Documents Applications and Grants

  • Total Patents Families

  • 4

    Granted

  • 12

    Pending

  • Expiring in next 12 mo

35Pharma Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4653010-A1 Activin receptor type iib traps for use in improving body composition Pending 14-May-2024
US-20260092096-A1 Activin receptor type iib variants and uses thereof Pending 14-May-2024
EP-4774008-A1 Combination therapy with actriib receptor variants and glp-1 agonists Pending 08-Sep-2023
US-20260193317-A1 Combination therapy with actriib receptor variants and glp-1 agonists Pending 08-Sep-2023
WO-2025050218-A1 Combination therapy with actriib receptor variants and glp-1 agonists Inactive 08-Sep-2023 A61P3/00
To view 35Pharma’s complete patent history, request access »

35Pharma Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

35Pharma Former Investors (10)

Investor Name Investor Type Holding Investor Since Participating Rounds
Columbia Threadneedle Investments Asset Manager Minority
Deep Track Capital Venture Capital Minority
Frazier Healthcare Partners PE/Buyout Minority
Janus Henderson Investors Asset Manager Minority
Logos Capital Hedge Fund Minority
You’re viewing 5 of 10 investors. Get the full list »

Ready to get started?

Request a free trial

35Pharma FAQs

  • When was 35Pharma founded?

    35Pharma was founded in 2021.

  • Where is 35Pharma headquartered?

    35Pharma is headquartered in Montreal, Canada.

  • What is the size of 35Pharma?

    35Pharma has 45 total employees.

  • What industry is 35Pharma in?

    35Pharma’s primary industry is Drug Discovery.

  • Is 35Pharma a private or public company?

    35Pharma is a Private company.

  • What is the current valuation of 35Pharma?

    The current valuation of 35Pharma is .

  • What is 35Pharma’s current revenue?

    The current revenue for 35Pharma is .

  • How much funding has 35Pharma raised over time?

    35Pharma has raised $70M.

  • Who are 35Pharma’s investors?

    Columbia Threadneedle Investments, Deep Track Capital, Frazier Healthcare Partners, Janus Henderson Investors, and Logos Capital are 5 of 10 investors who have invested in 35Pharma.

  • When was 35Pharma acquired?

    35Pharma was acquired on 14-Apr-2026.

  • Who acquired 35Pharma?

    35Pharma was acquired by GSK.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process